diazepinomicin
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00338026)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)=CCC/C(C)=C/CC/C(C)=C/CN1C(=O)c2cccc(O)c2Nc2c(O)cc(O)cc21- Mol. weight
- 462.59 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL550961 ↗
Also known as
- 4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo(b,e)(1,4)diazepin-11-one
- diazepinomicin
- diazepinomicin
- eco-4601
- eco-4601
- eco-4601
- tln4601
- tln 4601
- tln-4601
- tln-4601
- tln-4601
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00730262 | Phase 2 | Aug 1, 2008 | Thallion Pharmaceuticals, University of Toronto |
| NCT00338026 | Phase 1 | Feb 1, 2006 | McGill University, Thallion Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Thallion Pharmaceuticals | For profit | 2 | 2 | 2 | 2006 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1